Viking Therapeutics Reports $128M Net Loss and Increased Operating Expenses in Latest Quarter

Viking Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company, which focuses on developing therapies for metabolic and endocrine disorders, recorded no revenue during the quarter, consistent with its previous fiscal periods. Operating expenses surged to $132.6 million for the three months ended June 30, 2026, compared to $74.6 million for the same period in 2025, marking an increase of 77.7%. The increase was primarily driven by a 92.4% rise in research and development expenses, which totaled $115.8 million, reflecting the company's ongoing clinical trials, particularly for its lead drug candidate VK2735.

The company's net loss for the quarter was $128.0 million, compared to a loss of $65.6 million in the prior year, resulting in a basic and diluted net loss per share of $1.10, up from $0.58. For the six months ended June 30, 2026, the net loss reached $286.3 million, significantly higher than the $111.2 million loss reported for the same period in 2025. The increase in losses is attributed to heightened clinical trial activities and operational costs as Viking advances its drug candidates through various stages of development.

In terms of operational metrics, Viking's total assets decreased to $521.9 million as of June 30, 2026, down from $715.7 million at the end of 2025. This decline was primarily due to a reduction in cash and cash equivalents, which fell to $125.8 million from $165.8 million. The company also reported an increase in current liabilities, which rose to $109.7 million, compared to $76.7 million at the end of the previous fiscal year. Viking's employee headcount stood at 65 as of June 30, 2026, reflecting its ongoing investment in human resources to support its clinical development efforts.

Strategically, Viking has made significant moves, including the initiation of a new At-The-Market Equity Offering Sales Agreement on July 29, 2026, allowing the company to sell shares of its common stock to raise additional capital. The company also terminated its previous stock repurchase program and authorized a new program to repurchase up to $500 million in shares over the next three years. These actions are part of Viking's strategy to bolster its financial position as it navigates the costly and time-consuming process of drug development.

Looking ahead, Viking Therapeutics anticipates continued operating losses as it progresses through its clinical trials and seeks regulatory approvals for its drug candidates. The company believes its current cash reserves will be sufficient to fund operations through at least September 30, 2027. However, it acknowledges the need for additional capital to support ongoing and future development activities, which may include public or private equity offerings. The company remains focused on advancing its pipeline, particularly VK2735, which is currently in Phase 3 clinical trials, and VK2809, which has shown promising results in earlier studies.